{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:21:51Z","timestamp":1778721711764,"version":"3.51.4"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T00:00:00Z","timestamp":1708819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004263","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do estado do Rio Grande do Sul","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Induced pluripotent stem cells (iPSCs) are reprogrammed cells with a remarkable capacity for unlimited expansion and differentiation into various cell types. Companies worldwide are actively engaged in developing clinical-grade iPSC lines to address the needs of regenerative medicine, immunotherapies, and precision medicine. However, ensuring the safety and quality of iPSCs is essential, with adherence to Good Manufacturing Practices (GMP) and ethical considerations being paramount. Perinatal cell and tissue banks, such as umbilical cord (UC) blood and tissue banks, are emerging as ideal sources for generating iPSCs due to their unique characteristics and GMP compliance. These banks provide access to immature cells with limited environmental exposure, known family and medical histories of donors, and readily available resources, thereby reducing the time and cost associated with personalized treatment strategies. This study describes the establishment of the first clinical-grade iPSC lines from umbilical cord mesenchymal stromal cells in Brazil. The process involved rigorous quality control measures, safety assessments, and adherence to regulatory standards, resulting in iPSCs with the necessary characteristics for clinical use, including sterility, genomic integrity, and stability. Importantly, the study contributes to the development of a Current Good Manufacturing Practice-compliant iPSC production pipeline in Brazil, using commercially available, chemically defined, and xeno-free products, along with validation by national outsourced laboratories, thereby facilitating the adoption of this technology within the country. The study emphasizes Brazil\u2019s contribution to the progress of translational medicine and the promotion of scientific advancements within the field of regenerative and precision medicine.<\/jats:p>","DOI":"10.1093\/stcltm\/szae010","type":"journal-article","created":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T17:46:17Z","timestamp":1708883177000},"page":"454-461","source":"Crossref","is-referenced-by-count":5,"title":["Manufacturing Parameters for the Creation of Clinical-Grade Human-Induced Pluripotent Stem Cell Lines From Umbilical Cord Mesenchymal Stromal Cells"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5688-3015","authenticated-orcid":false,"given":"Liziane Raquel","family":"Beckenkamp","sequence":"first","affiliation":[{"name":"Hemocord Biotecnologia , Tecnosinos\u2014Technologic Park, S\u00e3o Leopoldo, RS , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila Gomes","family":"da Silva","sequence":"additional","affiliation":[{"name":"Hemocord Biotecnologia , Tecnosinos\u2014Technologic Park, S\u00e3o Leopoldo, RS , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f4nica Luiza Immig","family":"Von Hohendorff","sequence":"additional","affiliation":[{"name":"Hemocord Biotecnologia , Tecnosinos\u2014Technologic Park, S\u00e3o Leopoldo, RS , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolyn Sassi","family":"Ogliari","sequence":"additional","affiliation":[{"name":"Hemocord Biotecnologia , Tecnosinos\u2014Technologic Park, S\u00e3o Leopoldo, RS , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,2,25]]},"reference":[{"key":"2024051411062726000_CIT0001","first-page":"523","article-title":"Pluripotent stem cell-based cell therapy\u2014promise and challenges","volume-title":"Cell Stem Cell","author":"Yamanaka","year":"2020"},{"key":"2024051411062726000_CIT0002","first-page":"485","article-title":"Recent trends in research with human pluripotent stem cells: impact of research and use of cell lines in experimental research and clinical trials","volume-title":"Stem Cell Rep","author":"Guhr","year":"2018"},{"key":"2024051411062726000_CIT0003","first-page":"546","article-title":"A Manually curated database on clinical studies involving cell products derived from human pluripotent stem cells","volume-title":"Stem Cell Rep","author":"Kobold","year":"2020"},{"key":"2024051411062726000_CIT0004","first-page":"1","article-title":"A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell\u2013derived allogeneic cell therapies","volume-title":"Cytotherapy","author":"Dashnau","year":"2023"},{"key":"2024051411062726000_CIT0005","first-page":"1128","article-title":"Bioprocess technologies that preserve the quality of iPSCs","volume-title":"Trends Biotechnol","author":"Polanco","year":"2020"},{"key":"2024051411062726000_CIT0006","first-page":"859","article-title":"Quality control guidelines for clinical-grade human induced pluripotent stem cell lines","volume-title":"Regen Med","author":"Sullivan","year":"2018"},{"key":"2024051411062726000_CIT0007","first-page":"1052","article-title":"Identification and re-consent of existing cord blood donors for creation of induced pluripotent stem cell lines for potential clinical applications","volume-title":"Stem Cells Transl Med","author":"Abberton","year":"2022"},{"key":"2024051411062726000_CIT0008","first-page":"408","article-title":"Public cord blood banks as a source of starting material for clinical grade HLA-homozygous induced pluripotent stem cells","volume-title":"Stem Cell Res Ther","author":"\u00c1lvarez-Palomo","year":"2022"},{"key":"2024051411062726000_CIT0009","first-page":"835321","article-title":"Creation of GMP-Compliant iPSCs from banked umbilical cord blood","volume-title":"Front Cell Dev Biol","author":"Tian","year":"2022"},{"key":"2024051411062726000_CIT0010","first-page":"113","article-title":"Establishment of induced pluripotent stem cells from human neonatal tissues","volume-title":"Hum Cell","author":"Fujioka","year":"2010"},{"key":"2024051411062726000_CIT0011","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-9477-9","article-title":"Cell-based assays using differentiated human induced pluripotent cells","author":"Mandenius","year":"2019","journal-title":"Cell-Based Assays Using iPSCs for Drug Development and Testing"},{"issue":"11","key":"2024051411062726000_CIT0012","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3390\/cells11111853","article-title":"Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy","volume":"11","author":"Nicholson","year":"2022","journal-title":"Cells"},{"key":"2024051411062726000_CIT0013","author":"Brasil, Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria"},{"key":"2024051411062726000_CIT0014","first-page":"315","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume-title":"Cytotherapy","author":"Dominici","year":"2006"},{"key":"2024051411062726000_CIT0015","first-page":"D757","article-title":"hPSCreg-the human pluripotent stem cell registry","volume-title":"Nucleic Acids Res","author":"Seltmann","year":"2016"},{"key":"2024051411062726000_CIT0016","first-page":"505","article-title":"Generation and comprehensive characterization of induced pluripotent stem cells for translational research","volume-title":"Regen Med","author":"MacArthur","year":"2019"},{"key":"2024051411062726000_CIT0017","first-page":"663","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume-title":"Cell","author":"Takahashi","year":"2006"},{"key":"2024051411062726000_CIT0018","first-page":"1038","article-title":"Autologous induced stem-cell\u2013derived retinal cells for macular degeneration","volume-title":"N Engl J Med","author":"Mandai","year":"2017"},{"key":"2024051411062726000_CIT0019","first-page":"2398","article-title":"iPLAT1: the first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study","volume-title":"Blood","author":"Sugimoto","year":"2022"},{"key":"2024051411062726000_CIT0020","first-page":"1720","article-title":"Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study","volume-title":"Nat Med","author":"Bloor","year":"2020"},{"key":"2024051411062726000_CIT0021","first-page":"2047","article-title":"Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes","volume-title":"Cell Stem Cell","author":"Ramzy","year":"2021"},{"key":"2024051411062726000_CIT0022","first-page":"100466","article-title":"Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device","volume-title":"Cell Rep Med","author":"Shapiro","year":"2021"},{"key":"2024051411062726000_CIT0023","first-page":"2297","article-title":"Relocating to a new facility: the challenge of a cord blood banking transferral in Brazil","volume-title":"Transfusion","author":"Ogliari","year":"2022"},{"key":"2024051411062726000_CIT0024","first-page":"546","article-title":"Human induced pluripotent stem cells: from cell origin, genomic stability, and epigenetic memory to translational medicine","volume-title":"Stem Cells","author":"Poetsch","year":"2022"},{"key":"2024051411062726000_CIT0025","first-page":"1952","article-title":"Induced pluripotent stem cells: advances in the quest for genetic stability during reprogramming process","volume-title":"Int J Mol Sci","author":"Turinetto","year":"2017"},{"key":"2024051411062726000_CIT0026","first-page":"102035","article-title":"Haplobanking induced pluripotent stem cells for clinical use","volume-title":"Stem Cell Res","author":"Sullivan","year":"2020"},{"key":"2024051411062726000_CIT0027","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-031-34567-8_7","article-title":"Advanced therapy products in Brazil: regulatory aspects","volume-title":"Regulatory Aspects of Gene Therapy and Cell Therapy Products: A Global Perspective","author":"Junior","year":"2023"},{"key":"2024051411062726000_CIT0028","first-page":"6305","article-title":"The challenge of bringing iPSCs to the patient","volume-title":"Int J Mol Sci","author":"Ortu\u00f1o-Costela","year":"2019"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/13\/5\/454\/57597728\/szae010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/13\/5\/454\/57597728\/szae010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T11:07:10Z","timestamp":1715684830000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/13\/5\/454\/7614009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,25]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,2,25]]},"published-print":{"date-parts":[[2024,5,14]]}},"URL":"https:\/\/doi.org\/10.1093\/stcltm\/szae010","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2024,2,25]]}}}